The International ITP Registry
A Multi-centre, Prospective Disease Registry for Adults Diagnosed With Primary Immune Thrombocytopenia (ITP) in International Countries
1 other identifier
observational
500
10 countries
44
Brief Summary
Primary immune thrombocytopenia (ITP) is an uncommon disease characterised by a low platelet count, which may cause the patient to have a higher risk or increased duration of bleeding. Individual hospitals only encounter a small number of ITP patients each year which makes it difficult to study this disease. By creating this disease registry, we will be able to build a more complete picture of ITP, including treatment practices, through collecting information about the condition from patients across several hospitals in several countries. Research of this kind will help future patients by providing doctors with information about ITP, and about how patients have been treated.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Longer than P75 for all trials
44 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
September 19, 2013
CompletedFirst Posted
Study publicly available on registry
October 28, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2020
CompletedOctober 27, 2016
July 1, 2016
5.9 years
September 19, 2013
October 26, 2016
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Disease progression of ITP
This will include response assessment to each treatment modality, incidence and characteristics of bleeding events, bone marrow results (if available), development of refractory ITP and effects of any medical intervention (whether beneficial or detrimental) in the overall severity of the disease, according to definitions described by the ITP International Working Group.
up to 24 months
Study Arms (1)
Primary Immune Thrombocytopaenia
Recently-diagnosed (i.e. \< 6 months) primary ITP adult patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group.
Eligibility Criteria
Adults recently-diagnosed with primary ITP will be prospectively enrolled into the registry. In cases where prospective data collection is not possible from initial diagnosis, eg if sites see mainly referred patients, those patients with pre-existing ITP of no longer than 6 months duration since diagnosis will be allowed into the registry, provided they are still prospectively being followed up or under ongoing review / treatment at the participating institution.
You may qualify if:
- Recently-diagnosed (i.e. \< 6 months) primary ITP adults patients (≥ 18 years) characterized by platelet counts less than 100x109/L as defined by the International Working Group1.
- Able to provide written consent for data to be included in the registry
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- South Eastern Sydney Local Health Districtlead
- GlaxoSmithKlinecollaborator
Study Sites (44)
Canberra Hospital
Canberra, Australian Capital Territory, Australia
St George Hospital
Sydney, New South Wales, 2217, Australia
Calvary Mater Newcastle
Sydney, New South Wales, Australia
Concord Hospital
Sydney, New South Wales, Australia
Liverpool Hospital
Sydney, New South Wales, Australia
Prince of Wales Hospital
Sydney, New South Wales, Australia
Flinders Medical Centre
Adelaide, South Australia, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
St Vincent's Hospital
Melbourne, Victoria, Australia
The Alfred
Melbourne, Victoria, Australia
Foscal
Busaramanga, Colombia
Hemato-Oncologos
Colombia, Colombia
Hospital Pablo Tobón Uribe
Colombia, Colombia
Mubarak Alkabeer Hospital
Kuwait City, Kuwait
Penang Hospital
George Town, Malaysia
Ampang Hospital
Kuala Lumpur, Malaysia
Subang Jaya Medical Centre
Kuala Lumpur, Malaysia
National University Hospital
Singapore, Singapore
Singapore General Hospital
Singapore, Singapore
ASAN Medical Centre
Seoul, South Korea
Samsung Medical Centre
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Seoul St Mary's Hospital
Seoul, South Korea
Severance Hospital
Seoul, South Korea
China Medical University Hospital
Dawan, Taiwan
Mackay Memorial Hospital
Dawan, Taiwan
National Cheng Kung University Hospital
Dawan, Taiwan
Taipei Veteran's General Hospital
Taipei, Taiwan
Taichung Veteran's General Hospital
Taiwean, Taiwan
Ramathibodi Hospital
Bangkok, Thailand
Siriraj Hospital
Bangkok, Thailand
Chiang Mai University
Chiang Mai, Thailand
Chulalongkorn University
Thailand, Thailand
Pramongkutlao College of MEdicine
Thailand, Thailand
Ankara Numune Training and Research Hosptial
Ankara, Turkey (Türkiye)
Ankara Oncology Training and Research Hospital
Ankara, Turkey (Türkiye)
Ankara University
Ankara, Turkey (Türkiye)
Pamukkale University Medical Faculty
Pamukkale, Turkey (Türkiye)
Dokuz Eylul University Medical Faculty
Turkey, Turkey (Türkiye)
Erciyes University Medical Faculty
Turkey, Turkey (Türkiye)
Gaziantep University Medical Faculty
Turkey, Turkey (Türkiye)
CASMU
Uruguay, Uruguay
Hospital Britanico
Uruguay, Uruguay
Hospital Militar
Uruguay, Uruguay
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Beng H Chong
SESLHD
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 24 Months
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 19, 2013
First Posted
October 28, 2013
Study Start
January 1, 2011
Primary Completion
December 1, 2016
Study Completion
December 1, 2020
Last Updated
October 27, 2016
Record last verified: 2016-07